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Introduction: Essential amino acid α-keto acid analogues (EAAs) are used in the 
treatment of chronic kidney disease (CKD) to delay the symptoms of uremia. However, it is 
unknown whether EAAs affect oxidative stress and inflammation present in acute renal 
injury, such as that produced by ischemia-reperfusion (I/R). 
Objective: The purpose of this study was to evaluate the effect of EAAs on renal I/R injury 
in Wistar rats. 
Materials and methods: Rats were divided into 11 groups (n = 6/group): two groups 
received physiological saline with or without I/R injury (45 min/24 h), six groups received 
EAAs (400, 800, or 1200 mg/kg/24 h/7d) with or without I/R injury (EAAs+I/R), and two 
groups received allopurinol (ALO) (50 mg/kg/24 h/7d) with or without I/R injury. 
Biochemical markers included creatinine and blood urea nitrogen (BUN), proinflammatory 
cytokines (IL-1β, IL-6, and TNF-α), renal damage markers (cystatin C, KIM-1, and NGAL), 
and markers of oxidative stress such as malondialdehyde (MDA) and total antioxidant 
activity (AOxT). 
Results: The EAAs- and ALO-treated groups had lower levels of creatinine, BUN, renal 
damage markers, proinflammatory cytokines, and MDA than their corresponding I/R 
groups; these changes related to the EAAs dosage. AOxT was lower in EAAs- and ALO-
treated groups than in corresponding I/R groups. 
Conclusions: This is the first report of the nephroprotective effects of EAAs against I/R 
injury. EAAs decreased the levels of biochemical markers, kidney injury markers, 
proinflammatory cytokines, and MDA while minimizing total antioxidant consumption. 
Keywords: Ischemia; reperfusion injury; renal insufficiency, chronic; inflammation; 
oxidative stress; models, theoretical. 
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Introducción. Los α-cetoanálogos de aminoácidos esenciales (EAAs) se utilizan en el 
tratamiento de la enfermedad renal crónica (ERC) para retrasar los síntomas de la uremia. 
Sin embargo, se desconoce si los EAAs afectan el estrés oxidativo y la inflamación 
presentes en la lesión renal aguda como en la producida por isquemia-reperfusión (I/R). 
Objetivo. Evaluar el efecto de las EAAs sobre la lesión renal por I/R en ratas Wistar. 
Materiales y métodos. Se emplearon 11 grupos de ratas (n= 6): dos grupos recibieron 
solución salina fisiológica con o sin lesión I/R (45 min/24 h), seis grupos recibieron EAAs 
(400, 800 o 1200 mg/kg/24). h/7d) con o sin lesión I/R (EAAs + I/R), y dos grupos 
recibieron alopurinol (ALO) (50 mg/kg/24 h/7d) con o sin lesión I/R. Los marcadores 
bioquímicos incluyeron creatinina y nitrógeno ureico en sangre (BUN), citoquinas 
proinflamatorias (IL-1β, IL-6 y TNF-α), marcadores de daño renal (cistatina C, KIM-1 y 
NGAL) y marcadores de estrés oxidativo como malondialdehído (MDA) y la actividad 
antioxidante total (AOxT). 
Resultados. Los grupos tratados con EAAs y ALO tuvieron niveles inferiores de 
creatinina, BUN, marcadores de daño renal, citocinas proinflamatorias, AOxT y MDA que 
los grupos I/R correspondientes fue menor en los grupos con EAAs y ALO que en los 
grupos I/R correspondientes. 
Conclusiones. Este es el primer informe de los efectos nefroprotectores de las EAAs 
contra la lesión I/R. Los EAAs disminuyeron los niveles de marcadores bioquímicos, 
marcadores de lesión renal, citoquinas proinflamatorias y MDA, a la vez que minimizan el 
consumo total de antioxidantes. 
Palabras clave: isquemia; daño por reperfusión; insuficiencia renal crónica; inflamación; 
estrés oxidativo; modelos teóricos. 
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Essential amino acid -keto acid analogues (EAAs) are used as conservative treatment of 
chronic kidney disease (CKD) with the intention of reducing the production of metabolites 
of nitrogen degradation and thereby improving the glomerular filtration rate and delaying 
the need for substitution treatment (1). The beneficial effect of EAAs along with a low-
protein diet in treating CKD was first described in the 1970s (2), and this treatment is still 
used. A recent meta-analysis reported that EAAs can delay the progression of CKD by 
limiting hyperphosphatemia, preventing hyperparathyroidism, and improving the control of 
arterial blood pressure and malnutrition. EAAs are recommended in the treatment of 
stages 3 to 5 CKD (3). 
However, it is not clear whether EAAs have other beneficial effects, especially in the early 
stages of CKD or in acute kidney injury (AKI). AKI can be caused by acute tubular necrosis 
as a result of various types of ischemia. Renal ischemia is observed in a variety of clinical 
situations, such as recovery after cardiac arrest, liver and kidney transplantation, and 
partial nephrectomy. AKI observed after ischemia is characterized by decreased 
glomerular filtration rate, tubular necrosis, and increased renal vascular resistance. These 
changes can cause damage to tubular cells through the release of reactive oxygen 
species (ROS) and nitric oxide, and increased intracellular calcium concentration, which 
can in turn trigger mitochondrial damage through the depletion of antioxidants, cell-
mediated cytotoxicity, and an inflammatory response (4). These processes are similar to 
those occurring in CKD, in which a series of events triggers the process of fibrosis or 
scarring through a cytokine-mediated inflammatory response, which can activate 
extracellular matrix-producing cells in the glomerulus and tubules, and lead to the repair or 
scarring of various renal components (5). 
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Ischemia–reperfusion (I/R) injury occurs when the blood supply is cut off for a prolonged 
period of time and is then suddenly perfused with oxygenated blood (6). This process is 
characterized by the release of ROS and an intense inflammatory response provoked by 
the cellular response to the damaged tissue. I/R injury can be studied in animal models 
involving bilateral ischemia or heminephrectomy followed by ischemia of the remaining 
kidney. Bilateral ischemia is the preferred model because of its similarity to the 
pathological process in humans (7,8). Heminephrectomy has been used to evaluate the 
nephroprotective activity of drugs such as allopurinol (ALO), rosuvastatin, aliskiren and 
rutin that are considered as nephroprotective (8-11). 
EAAs may provide new agents for nephroprotection strategies, mainly for treating AKI and 
the early stages of CKD. Understanding whether EAAs have nephroprotective activity is 
the first step in developing new therapeutic strategies for the use of EAAs as more than a 
nutritional supplement. The principal objective of this study was to evaluate the effects of 
EAAs on the inflammatory response and oxidative stress in a model of renal damage 
caused by I/R injury in Wistar rats. As secondary objectives, it was initially evaluated to 
establish the dose to be used in order not to generate hepatotoxicity or nephrotoxicity 
through biochemical markers and renal damage, based on this established dose, the 
nephroprotective effect was evaluated through biochemical markers, proinflammatory 
mediators and oxidative stress markers. Finally, the effect of EAAs on various typical 
markers of renal damage and histological changes in renal architecture post I/R with and 
without administration of the selected dose of EAAs was evaluated. 
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Materials and methods 
Animals 
Experiments were performed using Wistar rats weighing 250–300 g in the Pharmacology 
and Toxicology Department of the Medicine Faculty at the Universidad Autónoma de 
Nuevo León, Mexico. All animals were maintained in polypropylene cages at a standard 
temperature (23-27°C) with 12 h light/dark periods and ad libitum access to water and 
standard food for rodents (Prolab diet 2500). Every experiment complied with the Mexican 
Official Norm NOM-062-ZOO-1999 specifications and was approved by the committee for 
the institutional care and use of laboratory animals with the registration number (HI17-
00001). 
Experimental design 
The animals were randomly divided into 11 groups with six rats in each group. The first 
five groups were used for evaluation of toxicity and groups 6 to 11 were used to evaluate 
nephroprotection. All doses evaluated were adjusted to a volume of 0.5 mL (figure 1). 
Chemicals 
Saline solution (CS PISA® solution, GDL México, sodium chloride 0.9%), alopurinol 
(Zyloprim® tablets, Aspen Port Elizabeth Pty, Ltd, Reg. No. 86270 SSA IV), EAAs 
(Cetolán Laboratorios Columbia® Reg. No. 122M2016 SSA IV), xylazine (Sedaject, 
Vedilab S.A. de C.V. Reg. SAGARPA Q-0088-122), ketamine (Anesket, PiSA 
Agropecuaria, S.A. de C.V. Reg. SAGARPA Q7833-028)  
The rats were anesthetized with xylazine (10 mg/kg, intraperitoneally (ip) and ketamine 
(100 mg/kg, ip). A small incision was made at the midline of the abdomen, through which 
the renal pedicle was occluded with microvascular clamps, and adequate occlusion was 
verified by cyanotic changes in both kidneys. The microvascular clamps were removed 
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after 45 min to induce reperfusion, which was confirmed by observation of blood flow 
restoration. The abdominal incision was closed with a 4-0 suture. All experiments were 
performed under aseptic conditions. The animals were monitored for 24 h and were 
allowed ad libitum access to water and food. Rats of sham group received the same 
surgical procedure but without I/R. Every animal was euthanized, and blood and kidney 
tissue samples were obtained for evaluation. 
Blood and tissue samples 
Blood was collected from each animal, allowed to clot, and centrifuged at 3,500 rpm for 15 
min, and the serum was separated for later measurement of the concentrations of 
proinflammatory cytokines, biochemical markers, and biomarkers of kidney injury. The 
kidneys were removed and divided longitudinally. One side was placed in a cryotube and 
immediately frozen in dry ice for later measurement of the concentrations of oxidative 
stress markers. The other side was fixed with formaldehyde in phosphate buffer (pH 7.4) 
for 24 h, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) 
to evaluate the histological alterations. 
Measurement of proinflammatory cytokine concentrations 
Serum concentrations of the proinflammatory cytokines interleukin 6 (IL-6), interleukin 1-
beta (IL-1β), and tumor necrosis factor-alpha (TNF-α) were measured using commercial 
sandwich ELISA kits (Rat IL-6 ELISA Development Kit, Rat IL-1β ELISA Development Kit, 
and Rat TNF-α ELISA Development Kit, respectively, PeproTech, Mexico City, México). 
Avidin–peroxidase and 2,2-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid were used as 
the chromogen, and the absorbance was measured by spectrophotometry at 405 nm. 
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Biochemical markers 
The serum concentrations of total proteins (TPs), albumin (Alb), urea nitrogen (BUN), 
creatinine (Creat), uric acid (UA), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP) 
were measured using an ILAB-Aries self-analyzer spectrophotometer using diagnostic kits 
(Instrumentation Laboratory, Milan, Italy) according to the supplier’s specifications. 
Kidney injury biomarkers 
The serum levels of cystatin C (CysC), neutrophil gelatinase associated lipocalin (NGAL), 
and kidney injury molecule-1 (KIM-1) were measured using commercial ELISA-sandwich 
kits (Quantikine ELISA, Mouse/Rat Cystatin C Immunoassay, R&D Systems, (Minneapolis, 
MN, USA), Lipocalin-2 (NGAL) Rat ELISA Kit, Abcam 119602, Cambridge, MA, USA, KIM-
1 (TIM-1) Rat ELISA Kit, Abcam 119597, respectively). These were analyzed by 
spectrophotometry at 450 nm. 
Oxidative stress markers 
Malondialdehyde (MDA) concentration was measured using a thiobarbituric acid-reactive 
substance (TBARS) assay using a TBARS Assay Kit (Cayman Chemical Co., Ann Arbor, 
MI, USA). The reaction product, which is proportional to the concentration of MDA in the 
sample, was measured spectrophotometrically at 540 nm. The total antioxidant activity 
(AOxT) was measured in homogenized kidney tissue using a commercial kit (Antioxidant 
Assay Kit, Cayman Chemical Co.). AOxT activity included both enzymatic and 
nonenzymatic activities’and was measured by spectrophotometry at 405 nm. 
Statistical analysis 
The results are expressed as mean ± standard deviation (SD). The homogeneity of 
variance was first established, and variables with a normal distribution were analyzed 
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using analysis of variance with multiple group comparisons using Dunnett’s test and Prism 
software (v. 7.0; GraphPad, San Diego, CA, USA). A p-value of <0.05 was considered to 
be significant. 
Results 
Evaluation of toxicity 
EAAs did not cause liver or renal toxicity when given at the different doses. The only 
markers that differed significantly between some of the study groups and the sham group 
were BUN, Creat, NGAL, IL-1 , and MDA levels (table 1, figure 2). 
Effects of EAAs on damage induced by I/R injury 
Biochemical markers 
Compared with the levels in the saline group, the levels of some biomarkers were 
significantly elevated in the saline +I/R group: Creat, BUN, and ALT (figure 3). The levels 
of other biomarkers were significantly lower in the saline+ I/R group than in the 
salinegroup: TPs, Alb, and UA. Compared with the saline+I/R group, groups ALO50+I/R, 
EAAs-800+I/R, and EAAs-1200+I/R had significantly lower Creat and BUN levels. Group 
EAAs-400+I/R also had lower Creat and BUN levels, but the difference was significant only 
for Creat level. Of the other biochemical parameters, only ALT concentration was 
significantly lower in the EAAs-1200+IR group than in the saline+I/R group (figure 3). 
Kidney injury biomarkers 
The levels of renal damage indicators (CysC, KIM-1, and NGAL) were significantly higher 
in the saline+I/R group than in the salinegroup. These levels were significantly lower in the 
groups treated with ALO50 and EAAs at various doses than in the saline+I/R group (figure 
4). 
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Proinflammatory cytokines 
Compared with the saline group, the saline+I/R group has significantly higher serum levels 
of the proinflammatory cytokines IL-1β and TNF-α. Control group showed a tendency to 
increase IL-6 levels compared to sham group. Cytokine levels were significantly lower in 
the ALO50+IR group than in the saline+I/R group. A similar pattern was seen in groups 
treated with EAAs at various doses (figure 5). 
Oxidative stress markers 
AOxT was significantly higher in the saline+I/R group than in the salinegroup. AOxT was 
significantly lower in the ALO50+I/R and EAAs+I/R groups than in the saline+I/R group, 
and this effect increased with the dose of EAAs. The MDA level was significantly higher in 
the saline+I/R group than in the saline-only group. The increment in MDA level was 
significantly smaller in the ALO50+I/R and EAAs+I/R groups than in the saline+I/R group, 
and this effect increased with the dose of EAAs (fFigure 6). 
Histological analysis 
The saline-treated group showed a normal renal parenchyma and preserved tubules and 
glomeruli, whereas the I/R group showed necrosis of the tubular epithelium in 90% of the 
medulla and 80% of the cortex. The ALO50+I/R group showed ischemic necrosis in 50% 
of the cortex and acute necrosis of the distal convoluted tubule The other EAAs+IR groups 
showed similar effects as those observed in the ALO50+I/R group (figure 7). 
Discussion 
CKD is currently considered to be a threat to global health as the number of patients 
increases rapidly (12). CKD is characterized by the development of glomerulosclerosis and 
interstitial fibrosis, and involves the interactions of various factors such as angiotensin II, 
growth factors, cytokines, and oxygen metabolites (13). 
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The restriction of proteins in the diet is an important therapy for people with CKD. Keto 
acid (KA) effects have been evaluated in patients with CKD on a protein-restricted diet (14) 
but not in AKI patients. One study compared the efficacy of a low-supplemented protein 
diet (LPD) with keto acids (LPD+KA) and an LPD alone in stopping the development of 
kidney injury associated with CKD in a 5/6 nephrectomy model in Sprague Dawley rats 
(15). This animal model of CKD is characterized by proteinuria, decreased renal function, 
glomerular sclerosis, and tubulointerstitial fibrosis. Protein restriction decreased the extent 
of these changes. The effect was greater in the LPD+KA group than in the LPD group, and 
the LPD+KA group had lower serum levels of BUN and Creat compared with the LPD 
group (15).In our current study, animals treated with various doses of EAAs also had lower 
BUN and creatinine levels, and this effect was dose dependent, in addition to presenting 
normal liver enzyme levels so it was shown that at these doses the EAAs were neither 
nephrotoxic or hepatotoxic. However, the levels of Alb, TPs, and UA did not decrease. 
These findings suggest that EAAs may have protected the kidneys from progressive injury 
by correcting the protein malnutrition in the remnant kidney tissue. 
On the other hand , in the renal I/R model, the levels of mediators of kidney damage, such 
as MCP-1, KIM-1, and CysC increase with reperfusion time (16). We found that the levels 
of some of these damage mediators, such as KIM-1, CysC, and NGAL, decreased 
considerably in the EAAs-treated groups that received the I/R injury. These data support 
the nephroprotective effect of EAAs. 
CKD can be exacerbated by oxidative stress, which promotes the production of reactive 
carbonyl compounds and lipoperoxides that lead to advanced glycosylation accumulation 
and lipoxidation. ROS react with nitric oxide to produce reactive cytotoxic nitrogen species 
that are capable of producing nitrate proteins that can damage other molecules (17). 
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Oxidative stress plays an important role in the development and progression of sclerosis 
and fibrosis in the remnant tissue in models of chronic renal failure (17,18). A low-protein 
diet, with or without KAs, has an antioxidant effect in humans with CKD and animal models 
of CKD (18,19). Previous studies in animals have found that EAAs combined with a low-
protein diet prevents weight loss, normalizes Alb levels, maintains nutritional status, and 
improves the protein malnutrition and injury caused by oxidative stress in the remnant 
kidney tissue (18). In addition, in rats submitted to 5/6 nephrectomy, the application of 
advanced oxidation protein products, which are associated with deterioration of renal 
function, imposes greater oxidative stress during the fibrotic process (15). Recently the 
nephroprotective effect of EEAs in early stages of diabetic nephropathy type 2 was 
described, mediated by the inhibition of oxidative stress through the decrease of MDA and 
increase of superoxido dismutase (20). In our study, we induced kidney damage in Wistar 
rats by I/R and found that EAAs modified the levels of oxidative stress markers, as shown 
by the attenuated damage in the renal cortex and decreased AOxT and production of MDA 
in EAAs/I/R rats compared with I/R rats. Again, these effects were EAAs dose dependent. 
The factors that initiate the cascade of cell damage and the inflammatory response after 
I/R leading to kidney damage are not completely understood. Increases in protein 
concentration have been described, such as the high-mobility group box-1 protein, which 
is released by kidney cells (particularly vascular and tubular cells) into the venous 
circulation after renal I/R damage. This protein induces a rapid release of cytokines (TNF-
α, G-CSF, IFN-Υ, IL-10, IL-1β, IL-6) into the systemic circulation (21,22). One study has 
reported decreases in the levels of IL-1β, IL-6, and TNF-α in patients receiving peritoneal 
dialysis and treated with KAs (18). In a rat experimental model with 5/6 nephrectomy 
treated with KAs, IL-1β and IL-6 levels increased but TNF-α and IL-18 levels did not 
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change significantly (15). We also observed decreases in the levels of IL-1β, IL-6, and 
TNF-α and the kidney damage markers CysC, KIM, and NGAL in the EAAs-treated 
groups; this effect was dependent on the dose of EAAs. These findings suggest that EAAs 
decreased the inflammatory response to I/R injury. 
The inflammatory response is extremely important in the development of kidney damage; 
I/R models are relevant when wanting to demonstrate an anti-inflammatory effect resulting 
in delayed kidney damage. This has been demonstrated in several studies, such as the 
one published by Mori da Cunha, where in their I/R model they demonstrate a 
nephroprotective effect of the application of amniotic fluid stem cells with increased 
regulation of vascular endothelial growth factor, which is dose-dependent (23). Other 
studies have also demonstrated the relationship of other inflammatory markers in the use 
of EAAs, for example those involved in mineral and bone metabolism disorders mediated 
by FGF-23 and Klotho involved in inflammation, oxidative stress and energetic protein 
malnutrition in stages 3b and 4 of chronic renal disease, associated with low-protein diet. 
The nephroprotective effect observed in our study, in acute damage, has not been 
previously reported. This study opens up the possibility of EAAs efficacy in both acute and 
chronic CKD damage (24). 
In conclusion, we show for the first time that EAAs have a nephroprotective effect against 
renal I/R damage. EAAs decreased the levels of biochemical markers, markers of kidney 
damage, proinflammatory cytokines, and MDA, and this effect was related to the dose of 
EAAs. EAAs exerted these protective effects while avoiding the consumption of total 
antioxidants. There is the possibility of a continuous protective effect, even without a 
restriction of proteins, which would strengthen its use in early stages of chronic kidney 
disease as well as its potential application in acute kidney damage and transplantation of 
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solid organs to reduce injury by I/R or improve the response in non-optimal organs, so 
studies are required to evidence such applications. 
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 Table 1. Changes in the seric levels of biochemical markers of kidney damage and 
proinflammatory cytokines in the toxicity evaluation groups.  
 
Variable       Sham 
        ALO 
50 mg/kg 
       EAAs  
400 mg/Kg 
     EAAs  
800 mg/Kg 
   EAAs 
 1200 mg/Kg 
CysC 
(ng/mL) 
381,30±37,85 350,80±24,38 287,00±19,07 346,80±23,04 395,50±26,54 
KIM–1 
(pg/mL) 
24,96±9,85 38,98±2,91 26,28±6,40 53,53±21,07 29,23±8,06 
NGAL 
(pg/mL) 
113,3±15,4 169,5±13,1* 159,0±11,9 104,0±5,5 170,0±14,1* 
 IL-1β 
(ng/mL) 
0,35±0,19 0,41±0,09 0,82±0,06* 0,46±0,06 0,93±0,13* 
 IL-6 
(ng/mL) 
1,25±0,25 1,36±0,31 1,33±0,15 1,92±0,38 0,92±0,29 
 FNTα 
(ng/mL) 
1,05±0,28 0,79±0,14 0,93±0,25 1,14±0,23 0,82±0,20 
 MDA 
(uM) 
0,75±0,30 3,50±0,34*** 1,46±0,25 1,96±0,39* 1,97±0,27* 
 AOxT 
(mM) 
2,59±0,10 2,63±0,13 2,78±0,06 2,72±0,08 2,58±0,11 
ALO: allopurinol; EAAs: Essential amino acid α ketoacid analogues; CysC: Cystatin C; KIM-
1: kidney injury molecule-1; NGAL: neutrophil gelatinase associated lipocalin; IL-1β: 
interleukin 1 beta; IL-6: interleukin 6; FNT-α: tumor necrosis factor alpha; MDA: 
malondialdehyde; AOxT: activity of the total antioxidants. Values are expressed as 
mean+SD, Sham group vs. study groups. * p <0,05, ** p <0,01, *** p <0,001. 
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Figure 1. Experimental design of the study groups in the timeline. 
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Figure 2. Changes in the seric levels of biochemical markers in toxicity study depending of 
treated groups (2-5) and sham control (Group 1).  BUN: blood urea nitrogen; Creat: 
creatinine; UA: uric acid; TPs: total proteins; Alb: albumin; ALT: alanine aminotransferase; 
AST: aspartate aminotransferase; ALP: alkaline phosphatase; LDH: lactate 
dehydrogenase.; I/R: Ischemia-reperfusion; ALO: Allopurinol; EAAs: Essential amino acid  
α-ketoacid analogues. Values are expressed as mean+SD. * p <0,05, ** p <0,01. 
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Figure3. Changes in serum levels of biomarkers in the study of nephroprotection.  BUN: 
blood urea nitrogen; Creat: creatinine; UA: uric acid; TPs: total proteins; Alb: albumin; ALT: 
alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; 
LDH: lactate dehydrogenase.; I/R: Ischemia-reperfusion; ALO: Allopurinol; EAAs: Essential 
amino acid  α-ketoacid analogues. Saline group +I/R (7) vs. sham group (6) and treated 
groups (8-11) 
Values are expressed as mean+SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
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Figure 4. Changes in kidney injury biomarkers in the nephroprotection study . CysC: 
Cystatin C; KIM-1: kidney injury molecule-1; NGAL: neutrophil gelatinase associated 
lipocalin.; I/R: Ischemia-reperfusion; ALO: Allopurinol; EAAs: Essential amino acid  α-
ketoacid analogues. Saline group +I/R (7) vs. sham group (6) and treated groups (8-11). 
Values are expressed as mean+SD.  .* p<0.0001. 
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Figure 5. Changes in proinflammatory cytokines in the nephroprotection study . IL-1β: 
interleukin 1beta; IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; I/R: Ischemia-
reperfusion; ALO: Allopurinol; EAAs: Essential amino acid  α-ketoacid analogues. Saline 
group +I/R (7) vs. sham group (6) and treated groups (8-11). Values are expressed as 
mean+SD. , * p<0.01, ** p<0.001, *** p<0.0001. 
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Figure 6. Changes in oxidative stress markers in the nephroprotection study.. MDA: 
Malondialdehyde; AOxT: activity of the total antioxidants; I/R: Ischemia-reperfusion; ALO: 
Allopurinol; EAAs: Essential amino acid α-ketoacid analogues. Saline group +I/R (7) vs. 
sham group (6) and treated groups (8-11). Values are expressed as mean+SD. p<0.05, ** 
p<0.001, *** p<0.0001. 
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Figure 7. Histological findings in the study groups with and without damage by ischemia-
reperfusion (H&E, x40). a: S.S: Preserved tubules b: I/R: Acute tubular necrosis and 
intratubular cylinders. c: ALO + I/R: medulla with acute tubular necrosis of convoluted 
tubules. d: EAAs 400 + I/R: diffuse ischemic necrosis. e: EAAs 800 + I/R: acute necrosis of 
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juxtamedullary convoluted tubule. f: EAAs 1200 + I/R: Acute tubular necrosis of proximal 
tubules in medulla, preserved cortex.; I/R: Ischemia-reperfusion injury; ALO: Allopurinol; 
EAA: Essential amino acid α-ketoacid analogues. 
